Preimplantation genetic screening costs are divided between two distinct providers: your fertility clinic, which charges for the cellular biopsy of the embryos, and an external genetics laboratory, which charges for chromosomal analysis. Because overall totals depend heavily on whether laboratories bill per embryo or through multi-embryo batch tiers, you must request separate, written fee schedules from both your clinic and the reference lab before starting treatment to calculate your true out-of-pocket expense.
Navigating assisted reproduction requires balancing demanding clinical steps with intricate financial planning. When adding preimplantation genetic screening to an in vitro fertilization cycle, unexpected multi-facility invoices can quickly strain your budget if you do not know how clinics and diagnostic laboratories split their fees.
Biopsy Fees Versus Reference Laboratory Invoices for PGT-A
Preimplantation genetic screening, referred to clinically as preimplantation genetic testing for aneuploidies or PGT-A, is rarely billed as a single bundled line item. When you review an estimate from a reproductive endocrinology practice, the genetic testing line item almost always covers only the in-house embryology work. During this step, an embryologist uses micromanipulation lasers to safely remove several cells from the trophectoderm layer of a day-five or day-six blastocyst. The clinic bills you for this delicate laboratory labor, specialized equipment, and specimen preparation, but they generally do not perform the actual genetic sequencing on-site.
The biopsied cells are placed into specialized transport tubes, frozen, and dispatched via medical courier to an independent genetics reference laboratory. This third-party facility performs next-generation sequencing to evaluate the cellular sample for missing or extra chromosomes. Because the testing laboratory operates as an autonomous medical entity, they issue a separate invoice directly to you. If a patient does not realize this dual-facility structure exists, they may pay their clinic's procedural fee in full and later receive a surprising secondary bill from the external testing company.
Clinical practices and laboratory partnerships vary significantly across the country, as documented in regional provider patterns by the CDC's assisted reproductive technology reports. Some fertility centers have preferred arrangements with specific reference laboratories, while others permit patients to choose among several approved testing partners. Establishing clarity on where the clinic's billing ends and the outside laboratory's billing begins is the foundational step in building an accurate treatment budget.
Further reading: CDC: Assisted Reproductive Technology
How Embryo Yield and Batched Retrieval Cycles Alter the Total Bill
The overall cost of preimplantation testing is directly tied to the number of blastocysts your cycle produces and how your chosen genetics laboratory structures its fee tiers. Diagnostic laboratories generally use one of two billing methodologies: a flat-rate tier or an itemized per-embryo model. In a flat-rate batch model, the laboratory charges a set fee that covers testing for up to a predetermined maximum number of embryos. If your cycle yields fewer embryos than that cap, you still pay the full flat rate; if your yield exceeds the threshold, each additional embryo incurs a supplementary per-embryo fee.
Conversely, under a strict per-embryo billing schedule, you pay an individual fee for each blastocyst analyzed, sometimes paired with a baseline administrative accessioning charge. This model can be advantageous for individuals anticipating a modest embryo yield, but it can cause total expenses to escalate rapidly for patients with high ovarian reserve who produce a large cohort of testable blastocysts. Because clinical responses to ovarian stimulation cannot be predicted with absolute certainty, financial coordinators must provide both the baseline tier terms and the marginal overage rates before your cycle commences.
For patients undergoing ovarian stimulation who experience diminished ovarian reserve or advanced reproductive age, clinical guidelines from the American College of Obstetricians and Gynecologists note that evaluation and treatment approaches must account for individual physiological differences. Some patients choose to complete multiple egg retrievals before testing any embryos, a strategy known as embryo banking. Depending on laboratory policy, you may be permitted to combine biopsies from multiple cycles into a single testing submission to avoid paying repeated baseline batch fees, though you may incur clinic-level storage and biopsy fees after each individual retrieval.
Further reading: ACOG: Evaluating Infertility
Mandatory Procedural Add-Ons: ICSI, Cryopreservation, and Storage
Electing to perform genetic screening on your embryos introduces several mandatory clinical steps that each carry their own individual charges. The first procedural requirement is intracytoplasmic sperm injection, commonly known as ICSI. In standard in vitro fertilization, thousands of sperm are placed in a dish with an egg, allowing fertilization to occur spontaneously. However, stray sperm cells adhering to the outer shell of the fertilized egg can cross-contaminate the cellular biopsy with extraneous paternal DNA. To ensure accurate next-generation sequencing, most genetics laboratories mandate that clinics fertilize eggs exclusively through ICSI, which introduces an upstream procedure fee.
The second mandatory operational component is embryo cryopreservation. Because external genetic sequencing requires several business days to several weeks for processing and clinical review, blastocysts cannot be transferred back into the uterus during the initial retrieval cycle. Instead, the clinic must vitrify the embryos immediately following trophectoderm biopsy. Vitrification incurs both a technical freezing fee and an initial specimen storage fee, transforming the treatment plan into a freeze-all cycle.
Finally, keeping your embryos safely preserved while awaiting laboratory results and scheduling transfer creates recurring downstream costs. While clinics frequently bundle the first month or two of cryostorage into their freezing fee, ongoing storage beyond that introductory window is billed on a monthly, quarterly, or annual subscription basis. When planning your screening budget, you must account for these maintenance fees alongside the future cost of a frozen embryo transfer protocol, which includes thawing, endometrial preparation, monitoring, and the transfer procedure itself.
Navigating Insurance Denials and Fertility Benefit Mandates
In the United States, employer-sponsored health insurance and commercial health plans frequently treat preimplantation genetic screening differently from standard diagnostic fertility testing. While some plans provide partial coverage for diagnostic workups or basic cycle procedures, routine aneuploidy screening is widely categorized as an elective or non-covered procedure. Insurers often argue that aneuploidy screening does not cure infertility, leading to routine claim rejections unless strict medical necessity criteria, such as a known balanced chromosomal translocation in one of the parents, are met.
Even when an employer offers an enhanced fertility benefit carve-out, patients often encounter network coordination issues. A fertility clinic and its physicians may be entirely in-network with your primary carrier, but the independent genetics laboratory analyzing your biopsy samples may be contracted out-of-network. When an out-of-network facility handles your specimen, your benefits may apply higher deductibles, lower coinsurance percentages, or no coverage at all, resulting in unexpected balance billing.
To avoid unexpected liabilities, you must contact your insurance company's dedicated fertility division and request a comprehensive review of the specific billing codes associated with the procedure. Ask for coverage determinations regarding CPT code 89290 and 89291 for the clinical biopsy preparation, as well as the molecular pathology codes used by the genetics lab for chromosomal evaluation. Securing these written determinations before starting stimulation medication guarantees that you understand your out-of-pocket obligations before services are rendered.
Strategies to Lower Out-of-Pocket Preimplantation Genetic Testing Expenses
While preimplantation screening represents a significant financial investment, several actionable pathways exist to reduce or manage out-of-pocket costs. First, ask your clinic's billing department if their partner genetics laboratory offers a prompt-pay or self-pay discount. Many commercial genetics labs publish commercial list prices for insurance billing but offer heavily discounted self-pay cash rates for patients whose insurance policies explicitly exclude genetic screening. In many instances, taking advantage of a direct-pay cash discount is substantially less expensive than attempting to process the claim through an out-of-network insurance benefit with a high unmet deductible.
Second, evaluate whether the external laboratory provides financial hardship programs or multi-cycle warranty packages. Certain commercial genetics laboratories provide income-based sliding scales that discount testing fees for qualifying households. Other testing facilities offer risk-sharing programs where paying an upfront package rate covers testing across multiple retrieval attempts within a specified calendar year, protecting you against escalating fees if your initial cycle yields very few usable blastocysts.
Lastly, have an open, objective clinical discussion with your reproductive endocrinologist regarding whether preimplantation screening is clinically warranted for your specific diagnostic profile. Professional medical organizations emphasize that fertility care must be individualized rather than applied as a universal template. For younger patients with no personal history of recurrent miscarriage, chromosomal rearrangements, or unexplained implantation failures, the clinical utility of routine screening should be weighed carefully against the cumulative out-of-pocket expense of the biopsy, testing, and storage fees.
Further reading: ACOG: Evaluating Infertility
Written Quote Checklist: Questions to Ask Your Financial Coordinator
Before signing consents or submitting non-refundable deposits, schedule a dedicated consultation with your clinic's financial coordinator and request an itemized fee breakdown. Written financial estimates protect you from ambiguous verbal promises and ensure that every participating provider is accounted for. Arriving at this meeting with a systematic checklist allows you to uncover hidden administrative charges, medical transport surcharges, and secondary lab fees that are frequently omitted from general price sheets.
During this meeting, ask specifically which genetic laboratory receives your clinic's biopsies and whether that facility bills the patient directly or bills through the clinic. Inquire about the exact fee consequences if a cycle does not progress as expected. For example, you should clarify whether biopsy fees are fully refundable if none of your fertilized eggs survive to the blastocyst stage, and whether the genetics lab charges an accessioning fee if transport kits are shipped but never utilized.
Additionally, verify the financial policies governing indeterminate or inconclusive results. Although modern next-generation sequencing is highly sophisticated, a small fraction of embryo biopsies fail to yield an actionable diagnostic result due to degraded cellular DNA. Ask your coordinator whether the clinic charges an additional biopsy fee to thaw and resample an inconclusive embryo, and whether the reference laboratory analyzes re-biopsied samples at no charge or requires a second full testing fee.
Illustrative Scenarios
Unbundling Multi-Facility Invoices Prior to Cycle Start
An illustrative composite case involves a couple preparing for their first in vitro fertilization cycle with planned genetic screening. Their fertility clinic presented a single estimate covering egg retrieval, embryology, and embryo biopsy. By reviewing the fine print, the patients noted that the estimate explicitly excluded external molecular pathology fees. They contacted the designated reference laboratory directly, discovered that their insurance carrier classified the lab as out-of-network, and enrolled in the lab's upfront self-pay tier. This avoided unexpected balance billing and allowed them to coordinate a batched testing submission that accounted for all procedural add-ons prior to starting medication.
Key point: Always verify whether an IVF clinic's genetic screening quote includes the external laboratory analysis, and confirm self-pay discount options before testing begins.
Frequently asked questions
What is the difference between PGS and PGT-A on a billing quote?
PGS (preimplantation genetic screening) is the older medical term for what is now officially called PGT-A (preimplantation genetic testing for aneuploidies). On modern clinic estimates and laboratory billing quotes, these terms describe the exact same service: analyzing an embryo biopsy for numerical chromosomal abnormalities.
Do I have to pay genetic testing fees if no embryos reach the blastocyst stage?
If no embryos survive to day five or day six in the embryology laboratory, the cellular biopsy cannot take place, and your clinic should not bill you for the biopsy procedure. Similarly, because no cellular material is shipped to the external genetics lab, you will not incur the reference laboratory's testing invoice, though you should confirm whether administrative kit fees apply.
Is the cost of intracytoplasmic sperm injection included in the genetic screening fee?
No, ICSI is an independent laboratory procedure performed on the day of egg retrieval to facilitate fertilization and prevent parental DNA contamination. While genetics laboratories generally require ICSI as a prerequisite for accurate testing, your fertility clinic bills ICSI as a separate clinical line item on your primary treatment invoice.
Can I use funds from a Health Savings Account (HSA) or Flexible Spending Account (FSA) for PGT-A?
In most cases, out-of-pocket medical expenses associated with in vitro fertilization, including clinical biopsy fees and diagnostic laboratory testing of embryos, qualify as eligible medical expenses under IRS guidelines. However, you should obtain a letter of medical necessity from your reproductive endocrinologist and confirm plan eligibility with your account administrator beforehand.
Your next step
Request itemized financial disclosure sheets from both your fertility clinic and their contracted genetic reference laboratory today, specifically detailing the biopsy charge, laboratory tier caps, and per-embryo overage rates.